Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in ovarian cancer.
Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in ovarian cancer.
复制标题
DOI：
10.3892/or.15.1.21
复制
发表时间：
2006
期刊：
影响因子：
4.2
通讯作者：
J. Fujimoto;H. Toyoki;H. Sakaguchi;I. Jahan;S. Alam;T. Tamaya
中科院分区：
文献类型：
--
作者：
J. Fujimoto;H. Toyoki;H. Sakaguchi;I. Jahan;S. Alam;T. Tamaya
血管生成对于实体瘤的发生、生长和进展至关重要。环氧合酶(cox)-2在多种肿瘤中被认为是一种血管生成因子。这促使我们研究卵巢癌中cox-2表达和血管生成的临床意义。微血管计数与cox-2水平有显著相关性。Cox-2定位于癌细胞，而不在卵巢癌组织的基质细胞中。Cox-2水平随着病程进展而升高，且30例Cox-2高表达患者预后极差（33%），其余30例Cox-2低表达患者24个月生存率为67%。此外，cox-2水平与VEGF水平显著相关。与cox-2相关的VEGF可能对血管生成有促进作用。因此，长期给予cox-2抑制剂可能有效抑制晚期卵巢癌强化治疗后的再生或复发。
Angiogenesis is essential for the development, growth and advancement of solid tumors. Cyclooxygenase (cox)-2 is recognized as an angiogenic factor in various tumors. This prompted us to study the clinical implications of cox-2 expression and angiogenesis in ovarian cancer. There was a significant correlation between microvessel counts and cox-2 levels. Cox-2 localized in the cancer cells, but not in the stromal cells of ovarian cancer tissue. Cox-2 levels increased with the advancement, and the prognosis of the 30 patients with high cox-2 expression was extremely poor (33%), while the 24-month survival rate of the other 30 patients, those with low cox-2 expression, was 67%. Furthermore, cox-2 levels significantly correlated with VEGF levels. VEGF associated with cox-2 might work on angiogenesis with advancement. Therefore, long-term administration of cox-2 inhibitors might be effective on the suppression of regrowth or recurrence after intensive treatment for advanced ovarian cancer.